Q
QuantAbundanceAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

30,465 signal articles · 149 in last 24h · 154,208 total before filter · latest 27m ago
149last 24h
871last 7d
144● bullish (7d)
96● bearish (7d)
214publishers
AllMacro209Earnings108M&A125Regulatory21Product21Analyst18
✕ clear all filtersticker: NVOsentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
Omeros Q1 Earnings Call Highlights
MarketBeat134d agoneutral
Omeros Q1 Earnings Call Highlights

Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. Chairman and Chief Executive

Novo Nordisk A/S Q1 Earnings Call Highlights
MarketBeat134d agoneutral
Novo Nordisk A/S Q1 Earnings Call Highlights

Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices. Chi

Lexicon Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat139d agoneutral
Lexicon Pharmaceuticals Q1 Earnings Call Highlights

Lexicon Pharmaceuticals (NASDAQ:LXRX) executives highlighted progress across late-stage regulatory programs and efforts to bolster the company’s financial position during the company’s first-quarter 2026 earnings call on May 7. Chief Executive Officer Mike Exton said the company entered 2026 with o

Health Care Roundup: Market Talk
The Wall Street Journal141d agoneutral
Health Care Roundup: Market Talk

Find insight on Novo Nordisk, Hartalega, Smith & Nephew and more in the latest Market Talks covering Health Care.